(Q37724245)

22 August 2017

1 reference

title

Pharmacotherapy of uveitis (English)

1 reference

22 August 2017

0 references

1 reference

Frank F Lee

1

1 reference

22 August 2017

Charles Stephen Foster

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

1135-1146

1 reference

The possible impact of uveitis in blindness: a literature survey

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Corticosteroids and glaucoma risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Steroid-induced osteoporosis. Are your asthmatic patients at risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Use of methotrexate in the management of sight-threatening uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

The therapeutic use of azathioprine in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Immunosuppressive Therapy for Severe Chronic Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Azathioprine in active chronic iridocyclitis. A double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Mechanism of action for leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

The efficacy of sirolimus in the treatment of patients with refractory uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Granulomatous sclerouveitis. Regression of ocular lesions with cyclophosphamide and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Cyclophosphamide-induced remissions in advanced polyarteritis nodosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Short-term chlorambucil for refractory uveitis in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Behçet's disease: a new target for anti-tumour necrosis factor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Etanercept therapy in children with treatment-resistant uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Biological response modifier therapy for refractory childhood uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

Treatment of retinal vasculitis in Behçet's disease with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003713534

10.1517/14656561003713534

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference